XML 30 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Tables)
 9 Months Ended
Sep. 30, 2017
Commitments and Contingencies [Abstract]  
Summary of milestone payments
Milestones Date Met Payments 
      
(1) when Company initiates a Phase 1 Clinical Trial of a licensed product July 2012 $750,000 
(2) when Company initiates a Phase 2 Clinical Trial of a licensed product September 2016  750,000 
(3) when Company initiates a Phase 3 Clinical Trial of a licensed product In future  1,500,000 
(4) Biological License Application filing with U.S. FDA In future  1,750,000 
(5) First commercial sale In future  1,500,000 
(6) after the first $10,000,000 in net sales In future  1,500,000 
Total   $7,750,000 
Schedule of future minimum obligations on the lease

 

For the year ending December 31:      
2018   $ 431,085  
2019     431,594  
2020     431,958  
2021     431,958  
Thereafter     323,969  
Total   $ 2,050,564